RxDoctor Payments Data

Jillian Savage

Nurse Practitioner · Augusta, MENPI 1194267450

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (46.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Johnson & Johnson at 24.4% of the total. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,908in general payments, 2019–2025

Across 34 payments — averaging $56.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$466
  • AstraZeneca$337
  • Seagen Inc.$294
  • Astellas Pharma US Inc$233
  • Daiichi Sankyo Inc.$202
  • Incyte Corporation$136
  • plus $240 from 8 others

What the payments were for

  • Consulting fees$28015%
  • Food & beverage$73939%
  • Education$88947%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.

See all nurse practitioner providers in Maine

Medicare billing

Part B allowed, 2024
$12,967
Medicare patients
97
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide14$192,785
ImbruvicaIbrutinib11$162,867
Abiraterone Acetate31$101,072
EliquisApixaban16$10,560
OxycontinOxycodone Hcl13$10,349
Anastrozole98$2,194
Oxycodone Hcl25$768
Ondansetron Hcl46$688
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$622
Letrozole27$577
Prochlorperazine Maleate43$456
Ondansetron OdtOndansetron21$451
Dexamethasone21$372
Acyclovir28$338
Gabapentin16$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$466$192,78514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.

Other nurse practitioner in Augusta

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →